JP2022049005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022049005A5 JP2022049005A5 JP2021148619A JP2021148619A JP2022049005A5 JP 2022049005 A5 JP2022049005 A5 JP 2022049005A5 JP 2021148619 A JP2021148619 A JP 2021148619A JP 2021148619 A JP2021148619 A JP 2021148619A JP 2022049005 A5 JP2022049005 A5 JP 2022049005A5
- Authority
- JP
- Japan
- Prior art keywords
- ppm
- cancer
- values
- solid
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022172594A JP7291839B2 (ja) | 2020-09-15 | 2022-10-27 | 固体形態のｃｄｋ４阻害薬 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US63/078636 | 2020-09-15 | ||
| US202163240268P | 2021-09-02 | 2021-09-02 | |
| US63/240268 | 2021-09-02 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172594A Division JP7291839B2 (ja) | 2020-09-15 | 2022-10-27 | 固体形態のｃｄｋ４阻害薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022049005A JP2022049005A (ja) | 2022-03-28 |
| JP2022049005A5 true JP2022049005A5 (enExample) | 2022-05-10 |
| JP7260606B2 JP7260606B2 (ja) | 2023-04-18 |
Family
ID=78000744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148619A Active JP7260606B2 (ja) | 2020-09-15 | 2021-09-13 | 固体形態のｃｄｋ４阻害薬 |
| JP2022172594A Active JP7291839B2 (ja) | 2020-09-15 | 2022-10-27 | 固体形態のｃｄｋ４阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172594A Active JP7291839B2 (ja) | 2020-09-15 | 2022-10-27 | 固体形態のｃｄｋ４阻害薬 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12570641B2 (enExample) |
| EP (2) | EP4578450A3 (enExample) |
| JP (2) | JP7260606B2 (enExample) |
| KR (1) | KR20230069983A (enExample) |
| CN (1) | CN116507620B (enExample) |
| AU (1) | AU2021345531B2 (enExample) |
| DK (1) | DK4214202T3 (enExample) |
| ES (1) | ES3022913T3 (enExample) |
| FI (1) | FI4214202T3 (enExample) |
| HU (1) | HUE070846T2 (enExample) |
| MX (1) | MX2023003054A (enExample) |
| PL (1) | PL4214202T3 (enExample) |
| PT (1) | PT4214202T (enExample) |
| SI (1) | SI4214202T1 (enExample) |
| TW (2) | TWI809503B (enExample) |
| WO (1) | WO2022058871A1 (enExample) |
| ZA (1) | ZA202303655B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3061133T3 (en) | 2019-08-26 | 2026-03-31 | Arvinas Operations Inc | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| MX2023003054A (es) | 2020-09-15 | 2023-04-05 | Pfizer | Formas solidas de un inhibidor de cdk4. |
| WO2023100070A1 (en) * | 2021-12-02 | 2023-06-08 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| US20260027087A1 (en) | 2022-07-29 | 2026-01-29 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| KR20250054814A (ko) * | 2022-09-05 | 2025-04-23 | 티와이케이 메디슨즈, 인코포레이티드 | Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 용도 |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| WO2024201334A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof |
| CN121368483A (zh) | 2023-06-02 | 2026-01-20 | 辉瑞公司 | 雌激素受体降解剂与cdk4抑制剂的组合 |
| EP4719405A1 (en) | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| WO2025024388A1 (en) | 2023-07-21 | 2025-01-30 | Accutar Biotechnology Inc. | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| TW201105669A (en) | 2009-07-30 | 2011-02-16 | Irm Llc | Compounds and compositions as Syk kinase inhibitors |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| CN105111191B (zh) | 2015-07-21 | 2018-06-08 | 上海皓元生物医药科技有限公司 | 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途 |
| SG11201900328WA (en) * | 2016-07-13 | 2019-02-27 | Jason Marineau | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| BR112019002610A2 (pt) | 2016-08-15 | 2019-07-02 | Pfizer | piridopirimidinonas inibidoras de cdk2/4/6 |
| MD3784664T2 (ro) | 2018-04-26 | 2025-06-30 | Pfizer | Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline |
| MX2023003054A (es) | 2020-09-15 | 2023-04-05 | Pfizer | Formas solidas de un inhibidor de cdk4. |
-
2021
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko not_active Ceased
- 2021-09-13 PL PL21783049.6T patent/PL4214202T3/pl unknown
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-13 DK DK21783049.6T patent/DK4214202T3/da active
- 2021-09-13 US US18/245,039 patent/US12570641B2/en active Active
- 2021-09-13 FI FIEP21783049.6T patent/FI4214202T3/fi active
- 2021-09-13 CN CN202180071477.7A patent/CN116507620B/zh active Active
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 HU HUE21783049A patent/HUE070846T2/hu unknown
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en not_active Ceased
- 2021-09-13 EP EP25153633.0A patent/EP4578450A3/en active Pending
- 2021-09-13 SI SI202130288T patent/SI4214202T1/sl unknown
- 2021-09-13 PT PT217830496T patent/PT4214202T/pt unknown
- 2021-09-13 ES ES21783049T patent/ES3022913T3/es active Active
- 2021-09-13 EP EP21783049.6A patent/EP4214202B1/en active Active
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
-
2023
- 2023-03-16 ZA ZA2023/03655A patent/ZA202303655B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022186995A5 (enExample) | ||
| FI4214202T3 (fi) | Cdk4-estäjän kiinteät muodot | |
| JP2024503235A5 (enExample) | ||
| FI3986890T3 (fi) | Bentsisoksatsolisulfonamidijohdannaisia | |
| JP2014527042A5 (enExample) | ||
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| JP2016528179A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2022526438A5 (enExample) | ||
| CA3019450A1 (en) | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application | |
| JP2007521340A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| RU2012138892A (ru) | СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5,-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА | |
| JP2012533570A5 (enExample) | ||
| HRP20100166T1 (hr) | Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze | |
| JP2010501519A5 (enExample) | ||
| JP2012153722A5 (enExample) | ||
| JP2022540333A5 (enExample) | ||
| JP2014502599A5 (enExample) | ||
| JP2022071077A5 (enExample) | ||
| JP2018534289A5 (enExample) | ||
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| RU2014101626A (ru) | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты | |
| JP2012526766A5 (enExample) | ||
| JP2021535111A5 (enExample) |